Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + TACE
- Development stage
- Phase 3
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intra-arterial
01
Overview
Lenvatinib + TACE is a combination therapy that pairs the oral multikinase inhibitor lenvatinib with transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC). Lenvatinib inhibits vascular endothelial growth factor receptors (VEGFR1-3) and other receptor tyrosine kinases involved in tumor angiogenesis and proliferation. TACE is a minimally invasive interventional radiology procedure that delivers chemotherapy directly to liver tumors while simultaneously blocking their blood supply through embolization. The combination therapy has shown synergistic effects, with lenvatinib providing systemic disease control while TACE delivers localized tumor treatment. Clinical studies have demonstrated that this combination significantly improves overall survival, progression-free survival, and tumor response rates compared to either treatment alone, while reducing the need for repeated TACE procedures and better maintaining liver function.
- Other names
- lenvatinib plus TACETACE plus lenvatiniblenvatinib combined with TACETACE-lenvatinib combination therapy
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lenvatinib + TACE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + TACE.